Lurasidone as a potential therapy for bipolar disorder

Area of Science:

• Pharmacology
• Psychiatry

Background:

• Lurasidone is an atypical antipsychotic approved for schizophrenia and bipolar 1 depression.
• It exhibits potent antagonism at dopamine D2 and serotonin 5-HT2A/5-HT7 receptors, with partial agonism at 5-HT1A.

Purpose of the Study:

• To evaluate the efficacy and safety of lurasidone for treating depressive symptoms in adults with bipolar 1 disorder.

Main Methods:

• Two large, 6-week clinical trials assessed lurasidone monotherapy and adjunctive therapy against placebo.
• Symptom improvement was measured using the Montgomery-Åsberg Depression Rating Scale and Clinical Global Impression-Bipolar Severity scores.

Main Results:

• Lurasidone significantly improved depressive symptoms compared to placebo in both monotherapy and adjunctive settings.
• Discontinuation rates due to adverse events were low and comparable to placebo.
• Common adverse events included headache, nausea, somnolence, and akathisia, with minimal metabolic changes.

Conclusions:

• Lurasidone is an effective treatment option for bipolar 1 depression, demonstrating favorable tolerability and minimal metabolic impact.
• It may be a valuable alternative for patients at risk of metabolic abnormalities.